Rank Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 02-12-2024
- Paid Up Capital ₹ 4.90 M
as on 02-12-2024
- Company Age 54 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2020)
- Profit 3.10%
(FY 2020)
- Ebitda 3.23%
(FY 2020)
- Net Worth -2.21%
(FY 2020)
- Total Assets 1.95%
(FY 2020)
About Rank Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.90 M, as per Ministry of Corporate Affairs (MCA) records.
Deepak Datwani, Vimla Datwani, and Nitin Datwani serve as directors at the Company.
- CIN/LLPIN
U24231DL1970PLC005304
- Company No.
005304
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
02 Jun 1970
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rank Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepak Datwani  | Director | 28-Feb-2005 | Current |
| Vimla Datwani | Director | 26-Jul-1985 | Current |
| Nitin Datwani | Director | 28-Feb-2005 | Current |
Financial Performance and Corporate Structure Insights of Rank Pharmaceuticals.
Rank Pharmaceuticals Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 3.1% increase in profit. The company's net worth dipped by a decrease of 2.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rank Pharmaceuticals?
In 2018, Rank Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Western Apparels Private LimitedActive 48 years 5 months
Deepak Datwani, Vimla Datwani and 1 more are mutual person
- B V M Engineering Industries LimitedActive 52 years 10 months
Deepak Datwani, Vimla Datwani and 1 more are mutual person
- J B Exports Private LtdActive 40 years 9 months
Deepak Datwani, Vimla Datwani and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rank Pharmaceuticals?
Unlock and access historical data on people associated with Rank Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rank Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rank Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
